

IN THE SPECIFICATION:

Amend the specification as follows.

Insert the attached Sequence Listing after the abstract.

Page 3, replace the last paragraph with the following paragraph:

Certain peptides of full length VP22 protein which are especially preferred for making aggregates according to the invention are those which correspond in sequence to amino acid residues of: (a) 194-226 of full length VP22 and which is unlabelled (b) 194-226 of full length VP22 and which is labelled at the C terminal end of the VP22 peptide e.g. with a FITC fluorophore, (c) 191-226 of full length VP22 and which is unlabelled, and (d) 191-220 of full length VP22 and which is unlabelled. Peptides 194-226KRRRRR (SEQ ID NO:1) (wherein K is lysine and R is arginine following the one letter amino acid code) and 194-226K are further useful examples for these purposes. Other examples of such peptides are 194-226KR(X6), and 194-226KR(X8) and also 194-226 - X - R(X6) wherein x is an amino acid sequence such as an eight amino acid sequence, e.g. the eight amino acid epitope of ovalbumin (SIINF~~E~~KL (SEQ ID NO:2) according to the single amino acid code).

Page 11, replace the paragraph spanning lines 25-27 with the following paragraph:

5' CCC CCA CCA CTT CCC CTC TC 3' (SEQ ID NO:3).

This sequence is commercially available and is complementary to a segment of mRNA encoding an intracellular- adhesion molecule, or ICAM.